drugset / Trial / NCT06113302
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RandomizedSingle-groupOpen-labelSupportive care
Summary
To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.
Timeline
- Start
- 2024-03-01
- Primary completion
- 2028-06-02
- Completion
- 2028-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Luspatercept | Protein / enzyme biologic | — | Subcutaneous |